Lawson Kroeker Investment Management Inc. NE reduced its stake in Pfizer Inc. (NYSE:PFE – Free Report) by 3.5% during the 4th quarter, HoldingsChannel.com reports. The firm owned 210,776 shares of the biopharmaceutical company’s stock after selling 7,535 shares during the period. Lawson Kroeker Investment Management Inc. NE’s holdings in Pfizer were worth $5,592,000 as of its most recent SEC filing.
Several other hedge funds also recently added to or reduced their stakes in the stock. Synergy Asset Management LLC purchased a new position in Pfizer in the fourth quarter valued at approximately $63,000. Drystone LLC purchased a new position in shares of Pfizer during the fourth quarter worth approximately $3,868,000. Gries Financial LLC grew its position in shares of Pfizer by 6.8% during the fourth quarter. Gries Financial LLC now owns 29,246 shares of the biopharmaceutical company’s stock worth $776,000 after acquiring an additional 1,853 shares during the last quarter. Hanson & Doremus Investment Management grew its position in shares of Pfizer by 1.0% during the fourth quarter. Hanson & Doremus Investment Management now owns 139,121 shares of the biopharmaceutical company’s stock worth $3,691,000 after acquiring an additional 1,408 shares during the last quarter. Finally, Allen Capital Group LLC grew its position in shares of Pfizer by 10.2% during the fourth quarter. Allen Capital Group LLC now owns 125,582 shares of the biopharmaceutical company’s stock worth $3,332,000 after acquiring an additional 11,661 shares during the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
A number of equities analysts have recently issued reports on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research report on Wednesday, October 23rd. Bank of America restated a “neutral” rating and set a $29.00 target price on shares of Pfizer in a research report on Tuesday, December 10th. StockNews.com lowered shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 20th. Truist Financial decreased their price target on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. Finally, Wolfe Research started coverage on Pfizer in a report on Friday, November 15th. They set an “underperform” rating and a $25.00 price target for the company. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $31.92.
Pfizer Price Performance
Pfizer stock opened at $26.65 on Thursday. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54. The company has a market cap of $151.00 billion, a P/E ratio of 36.01, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64. The business has a fifty day moving average of $26.18 and a two-hundred day moving average of $27.91. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.
Pfizer (NYSE:PFE – Get Free Report) last announced its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The business had revenue of $17.70 billion during the quarter, compared to analysts’ expectations of $14.92 billion. During the same quarter last year, the business posted ($0.17) earnings per share. The business’s revenue for the quarter was up 31.2% on a year-over-year basis. As a group, analysts predict that Pfizer Inc. will post 2.94 earnings per share for the current fiscal year.
Pfizer Increases Dividend
The company also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, January 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.46%. This is a boost from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio (DPR) is currently 227.03%.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Featured Articles
- Five stocks we like better than Pfizer
- CD Calculator: Certificate of Deposit Calculator
- Kimberly-Clark: A Regal Opportunity in This Dividend King
- How to Most Effectively Use the MarketBeat Earnings Screener
- 5 Stocks With Above-Market Yields Just Raised Payments Further
- How to invest in marijuana stocks in 7 stepsĀ
- Arista Networks’ Stock Plunge: Buying Opportunity for Investors?
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.